Compare InMode Ltd (INMD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? InMode Ltd trades at $14.11 (market cap $809.93M), while Vertex Pharmaceuticals Incorporated trades at $514 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 157.5× InMode Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 29 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| INMD | VRTX | |
|---|---|---|
Market Cap | $809.93M | $127.55B |
Volume | 365,490 | 1,487,944 |
Sector | Health | Health |
52-Week High | $16.62 | $557.96 |
52-Week Low | $12.76 | $407.37 |
Typical Hold Time | 29 Days | 120 Days |
Enterprise Value | $313.27M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.01, up 0.14% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 earnings of $0.35 per share, beating expectations, and maintains a strong gross profit margin of 76.52%. Recent news includes the launch of Morpheus8 Cool and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The outlook is mixed: valuation metrics like P/E of 11.63 and EV/EBITDA of 4.48 appear attractive, but declining net income and bearish technicals pose risks. Analyst consensus is divided with 45.45% buy ratings, highlighting potential upside from strategic developments against execution challenges.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
